Banco Comercial Português, S.A. informs about estimated provisions against legal risk related to FX mortgage loans portfolio booked by Bank Millennium, S.A. in 3Q 2026
Attachment
Tag: GlobeNewswire
Company announcement – No. 54 / 2026
Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes
- Petrelintide achieved up to 9.2% mean body weight reduction at week 28 versus 2.0% with placebo
- At week 28, petrelintide demonstrated a HbA1c reduction of up to 0.65% versus an increase of 0.23% with placebo
- Safety and tolerability profile of petrelintide was consistent with that seen in the Phase 2 ZUPREME-1 trial
- Very low discontinuation rates due to gastrointestinal adverse events (1.9% for petrelintide versus 1.7% in placebo group)
- Data reinforce potential of petrelintide as a future first choice therapy for chronic weight management
Copenhagen, Denmark, October 7, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced positive topline results from the Phase 2 ZUPREME-2 trial evaluating the efficacy and safety of petrelintide versus placebo in 220 people living with overweight or obesity and type 2 diabetes (mean baseline BMI of 36.3 kg/m2; mean baseline HbA1c of 8.0%).
The trial met its primary endpoint, demonstrating that once-weekly subcutaneous injections of petrelintide (escalated every fourth week) resulted in statistically significant and clinically meaningful reductions in body weight from baseline after 28 weeks in all three treatment arms compared to placebo. Study participants achieved up to 9.2% mean weight loss from baseline using the efficacy estimand (range across treatment arms: 7.4-9.2%), compared to 2.0% with placebo, with results remaining largely consistent under the treatment regimen estimand. Petrelintide also demonstrated clinically relevant reduction in HbA1c across all treatment arms with participants achieving a placebo-adjusted HbA1c reduction of 0.61%-0.88%.
“These results further support the potential of petrelintide in chronic weight management and, for the first time, demonstrate its promise as a standalone treatment for those living with overweight or obesity and type 2 diabetes,” said David Kendall, MD, Chief Medical Officer at Zealand Pharma. “These data confirm the potential for clinically meaningful weight reduction with a promising and favorable tolerability profile. We are also encouraged by the improvements in glycemic control – a combination essential for supporting long-term, sustained benefits in people living with obesity and type 2 diabetes. Together with Roche, we look forward to investigating petrelintide in our recently initiated Phase 3 registrational program to address important unmet medical needs in chronic weight management.”
No unexpected safety signals were observed with petrelintide treatment. Petrelintide demonstrated a favorable tolerability profile largely comparable to placebo. The treatment discontinuation rate due to gastrointestinal adverse events (AEs) was 1.9% for participants treated with petrelintide versus 1.7% with placebo. The most frequently reported AEs were gastrointestinal-related, the vast majority of which were mild and occurred during the escalation period.
The safety and tolerability profile of petrelintide observed in ZUPREME-2 confirms the findings of the 42-week Phase 2 ZUPREME-1 trial in people with overweight or obesity without type 2 diabetes. The full trial results from ZUPREME-2 are expected to be presented at an upcoming scientific conference.
Zealand Pharma and Roche have started a Phase 3a program for petrelintide which consists of three trials: ZUPREME-3, ZUPREME-4, and ZUPREME-5, evaluating the efficacy and safety of once-weekly petrelintide versus placebo in people with obesity or overweight without type 2 diabetes, people with obesity or overweight with type 2 diabetes, and people with obesity or overweight and established cardiovascular disease, respectively. The three trials are expected to enroll approximately 7,000 participants in total and the first individuals have initiated treatment. For more information about the Phase 3 program, refer to Zealand Pharma Press Release no. 17 / 2026.
This company announcement discloses inside information pursuant to Article 17 of the Market Abuse Regulation (EU) No 596/2014.
About ZUPREME-2
ZUPREME-2 was a randomized, double-blind, placebo-controlled, parallel-group, multicenter, US-based Phase 2b clinical trial (NCT06926842). The trial compared three doses of once-weekly petrelintide with placebo, when added to a reduced-calorie diet and increased physical activity in participants with overweight or obesity and type 2 diabetes on metformin with or without an SGLT2 inhibitor.
The trial included a screening period, a dose escalation treatment period up to 16 weeks with dose escalation every fourth week followed by a maintenance treatment period until week 28, and a follow-up period after treatment was completed until week 38. ZUPREME-2 enrolled a total of 220 participants in the United States.
The primary endpoint in the trial is the percentage change in body weight from baseline to week 28. Secondary endpoints include, but are not limited to, body weight loss of ≥5% and ≥10%, absolute change in body weight, change in waist circumference, change in hemoglobin A1c (HbA1c), change in high-sensitivity C-reactive protein (hsCRP), change in fasting glucose, and change in fasting lipids.
For more information about the ZUPREME-2 clinical trial of petrelintide, please visit https://clinicaltrials.gov/study/NCT06926842.
About petrelintide
Petrelintide is a long-acting human amylin analog suitable for once-weekly subcutaneous administration that has been designed with chemical and physical stability with no fibrillation around neutral pH, allowing for co-formulation and co-administration with other peptides1. The hormone amylin is produced in the pancreatic beta cells and co-secreted with insulin in response to ingested nutrients. Amylin receptor activation has been shown to reduce body weight by restoring sensitivity to the satiety hormone leptin2,3, inducing a sense of feeling full faster.
In 2025, Zealand Pharma and Roche entered into an exclusive collaboration and licensing agreement to co-develop and co-commercialize petrelintide for people living with overweight and obesity. Petrelintide is currently being developed for chronic weight management as both a monotherapy agent and in combination with Roche’s GLP-1/GIP receptor dual agonist enicepatide (CT-388). A Phase 2 trial evaluating the combination of petrelintide and enicepatide (CT-388) is planned for initiation in the second half of 2026.
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health.
To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.
Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Cambridge, Massachusetts. Learn more at www.zealandpharma.com.
Forward-looking statements
This company announcement contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Pharma’s expectations or forecasts of future events regarding the research, development, and commercialization of pharmaceutical products, the timing of the company’s clinical trials and the reporting of data therefrom and the company’s significant events and potential catalysts in 2026 and financial guidance for 2026. These forward-looking statements may be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would”, and other words and terms of similar meaning. You should not place undue reliance on these statements, or the scientific data presented. The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect, and which include, but are not limited to, unexpected costs or delays in clinical trials and other development activities due to adverse safety events or otherwise; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; our ability to successfully market both new and existing products; changes in reimbursement rules and governmental laws and related interpretation thereof; government-mandated or market-driven price decreases for our products; introduction of competing products; production problems; unexpected growth in costs and expenses; our ability to effect the strategic reorganization of our businesses in the manner planned; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may reject, fail to approve or may delay approval of our drug candidates or expansion of product labelling; failure to obtain regulatory approvals in other jurisdictions; exposure to product liability and other claims; interest rate and currency exchange rate fluctuations; unexpected contract breaches or terminations; inflationary pressures on the global economy; and political uncertainty. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. All such forward-looking statements speak only as of the date of this press release/company announcement and are based on information available to Zealand Pharma as of the date of this release/announcement. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.
Zealand Pharma® is a registered trademark of Zealand Pharma A/S.
Contacts
Eric Rojas (Investors)
Vice President, Head of Investor Relations
erojas@zealandpharma.com
Neshat Anis Ahmadi (Investors)
Manager, Investor Relations
neahmadi@zealandpharma.com
Rachel James-Owens (Media)
Vice President, Corporate Communications & Media Relations
Email: RJamesOwens@zealandpharma.com
Andreas Hylleberg (Media)
Director, External Communications
Email: AHylleberg@zealandpharma.com
Amber Fennell, Jessica Hodgson, Sean Leous (Media)
ICR Healthcare
Email: ZealandPharma@icrhealthcare.com
+44 (0) 7739 658 783
Sources
1. Eriksson et al. Presentation at ObesityWeek, November 1–4, 2022, San Diego, CA.
Link: https://www.zealandpharma.com/media/0gnfxg4b/zp8396-sema-coformulation-obesityweek-2022.pdf.
2. Mathiesen et al. Eur J Endocrinol 2022;186(6):R93–R111.
3. Roth et al. Proc Natl Acad Sci U S A 2008;105(20):7257–7262.
Attachment
Company announcement – No. 54 / 2026
Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes
- Petrelintide achieved up to 9.2% mean body weight reduction at week 28 versus 2.0% with placebo
- At week 28, petrelintide demonstrated a HbA1c reduction of up to 0.65% versus an increase of 0.23% with placebo
- Safety and tolerability profile of petrelintide was consistent with that seen in the Phase 2 ZUPREME-1 trial
- Very low discontinuation rates due to gastrointestinal adverse events (1.9% for petrelintide versus 1.7% in placebo group)
- Data reinforce potential of petrelintide as a future first choice therapy for chronic weight management
Copenhagen, Denmark, October 7, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced positive topline results from the Phase 2 ZUPREME-2 trial evaluating the efficacy and safety of petrelintide versus placebo in 220 people living with overweight or obesity and type 2 diabetes (mean baseline BMI of 36.3 kg/m2; mean baseline HbA1c of 8.0%).
The trial met its primary endpoint, demonstrating that once-weekly subcutaneous injections of petrelintide (escalated every fourth week) resulted in statistically significant and clinically meaningful reductions in body weight from baseline after 28 weeks in all three treatment arms compared to placebo. Study participants achieved up to 9.2% mean weight loss from baseline using the efficacy estimand (range across treatment arms: 7.4-9.2%), compared to 2.0% with placebo, with results remaining largely consistent under the treatment regimen estimand. Petrelintide also demonstrated clinically relevant reduction in HbA1c across all treatment arms with participants achieving a placebo-adjusted HbA1c reduction of 0.61%-0.88%.
“These results further support the potential of petrelintide in chronic weight management and, for the first time, demonstrate its promise as a standalone treatment for those living with overweight or obesity and type 2 diabetes,” said David Kendall, MD, Chief Medical Officer at Zealand Pharma. “These data confirm the potential for clinically meaningful weight reduction with a promising and favorable tolerability profile. We are also encouraged by the improvements in glycemic control – a combination essential for supporting long-term, sustained benefits in people living with obesity and type 2 diabetes. Together with Roche, we look forward to investigating petrelintide in our recently initiated Phase 3 registrational program to address important unmet medical needs in chronic weight management.”
No unexpected safety signals were observed with petrelintide treatment. Petrelintide demonstrated a favorable tolerability profile largely comparable to placebo. The treatment discontinuation rate due to gastrointestinal adverse events (AEs) was 1.9% for participants treated with petrelintide versus 1.7% with placebo. The most frequently reported AEs were gastrointestinal-related, the vast majority of which were mild and occurred during the escalation period.
The safety and tolerability profile of petrelintide observed in ZUPREME-2 confirms the findings of the 42-week Phase 2 ZUPREME-1 trial in people with overweight or obesity without type 2 diabetes. The full trial results from ZUPREME-2 are expected to be presented at an upcoming scientific conference.
Zealand Pharma and Roche have started a Phase 3a program for petrelintide which consists of three trials: ZUPREME-3, ZUPREME-4, and ZUPREME-5, evaluating the efficacy and safety of once-weekly petrelintide versus placebo in people with obesity or overweight without type 2 diabetes, people with obesity or overweight with type 2 diabetes, and people with obesity or overweight and established cardiovascular disease, respectively. The three trials are expected to enroll approximately 7,000 participants in total and the first individuals have initiated treatment. For more information about the Phase 3 program, refer to Zealand Pharma Press Release no. 17 / 2026.
This company announcement discloses inside information pursuant to Article 17 of the Market Abuse Regulation (EU) No 596/2014.
About ZUPREME-2
ZUPREME-2 was a randomized, double-blind, placebo-controlled, parallel-group, multicenter, US-based Phase 2b clinical trial (NCT06926842). The trial compared three doses of once-weekly petrelintide with placebo, when added to a reduced-calorie diet and increased physical activity in participants with overweight or obesity and type 2 diabetes on metformin with or without an SGLT2 inhibitor.
The trial included a screening period, a dose escalation treatment period up to 16 weeks with dose escalation every fourth week followed by a maintenance treatment period until week 28, and a follow-up period after treatment was completed until week 38. ZUPREME-2 enrolled a total of 220 participants in the United States.
The primary endpoint in the trial is the percentage change in body weight from baseline to week 28. Secondary endpoints include, but are not limited to, body weight loss of ≥5% and ≥10%, absolute change in body weight, change in waist circumference, change in hemoglobin A1c (HbA1c), change in high-sensitivity C-reactive protein (hsCRP), change in fasting glucose, and change in fasting lipids.
For more information about the ZUPREME-2 clinical trial of petrelintide, please visit https://clinicaltrials.gov/study/NCT06926842.
About petrelintide
Petrelintide is a long-acting human amylin analog suitable for once-weekly subcutaneous administration that has been designed with chemical and physical stability with no fibrillation around neutral pH, allowing for co-formulation and co-administration with other peptides1. The hormone amylin is produced in the pancreatic beta cells and co-secreted with insulin in response to ingested nutrients. Amylin receptor activation has been shown to reduce body weight by restoring sensitivity to the satiety hormone leptin2,3, inducing a sense of feeling full faster.
In 2025, Zealand Pharma and Roche entered into an exclusive collaboration and licensing agreement to co-develop and co-commercialize petrelintide for people living with overweight and obesity. Petrelintide is currently being developed for chronic weight management as both a monotherapy agent and in combination with Roche’s GLP-1/GIP receptor dual agonist enicepatide (CT-388). A Phase 2 trial evaluating the combination of petrelintide and enicepatide (CT-388) is planned for initiation in the second half of 2026.
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health.
To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.
Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Cambridge, Massachusetts. Learn more at www.zealandpharma.com.
Forward-looking statements
This company announcement contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Pharma’s expectations or forecasts of future events regarding the research, development, and commercialization of pharmaceutical products, the timing of the company’s clinical trials and the reporting of data therefrom and the company’s significant events and potential catalysts in 2026 and financial guidance for 2026. These forward-looking statements may be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would”, and other words and terms of similar meaning. You should not place undue reliance on these statements, or the scientific data presented. The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect, and which include, but are not limited to, unexpected costs or delays in clinical trials and other development activities due to adverse safety events or otherwise; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; our ability to successfully market both new and existing products; changes in reimbursement rules and governmental laws and related interpretation thereof; government-mandated or market-driven price decreases for our products; introduction of competing products; production problems; unexpected growth in costs and expenses; our ability to effect the strategic reorganization of our businesses in the manner planned; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may reject, fail to approve or may delay approval of our drug candidates or expansion of product labelling; failure to obtain regulatory approvals in other jurisdictions; exposure to product liability and other claims; interest rate and currency exchange rate fluctuations; unexpected contract breaches or terminations; inflationary pressures on the global economy; and political uncertainty. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. All such forward-looking statements speak only as of the date of this press release/company announcement and are based on information available to Zealand Pharma as of the date of this release/announcement. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.
Zealand Pharma® is a registered trademark of Zealand Pharma A/S.
Contacts
Eric Rojas (Investors)
Vice President, Head of Investor Relations
erojas@zealandpharma.com
Neshat Anis Ahmadi (Investors)
Manager, Investor Relations
neahmadi@zealandpharma.com
Rachel James-Owens (Media)
Vice President, Corporate Communications & Media Relations
Email: RJamesOwens@zealandpharma.com
Andreas Hylleberg (Media)
Director, External Communications
Email: AHylleberg@zealandpharma.com
Amber Fennell, Jessica Hodgson, Sean Leous (Media)
ICR Healthcare
Email: ZealandPharma@icrhealthcare.com
+44 (0) 7739 658 783
Sources
1. Eriksson et al. Presentation at ObesityWeek, November 1–4, 2022, San Diego, CA.
Link: https://www.zealandpharma.com/media/0gnfxg4b/zp8396-sema-coformulation-obesityweek-2022.pdf.
2. Mathiesen et al. Eur J Endocrinol 2022;186(6):R93–R111.
3. Roth et al. Proc Natl Acad Sci U S A 2008;105(20):7257–7262.
Attachment
On 7 October 2026, the Board of AB Akola Group, with its registered office at Subačiaus St. 5, Vilnius, Lithuania, company code 148030011 (the Company), approved the draft profit (loss) distribution for the Company’s 2025/2026 financial year ended 30 June 2026. The draft will be submitted for approval to the Annual General Meeting of Shareholders of the Company to be held on 28 October 2026.
The Board proposes to allocate EUR 19,825,017 for the payment of dividends, corresponding to EUR 0.12 per share of the Company before taxes (calculated excluding the Company’s own shares).
Persons who are shareholders of the Company at the end of the rights accounting date, which is 12 November 2026, will be entitled to receive dividends.
The final decision on the distribution of the Company’s profit and the payment of dividends will be made by the Annual General Meeting of Shareholders of the Company on 28 October 2026.
The Company will provide additional information on the procedure and timing for the payment of dividends once the General Meeting of Shareholders adopts a resolution to pay dividends.
Sincerely,
CEO Darius Zubas
Additional information can be provided by:
Mažvydas Šileika,
AB Akola Group Deputy CEO for Finance and Investments
Email: m.sileika@akolagroup.lt
Phone. +370 619 19 403
On 7 October 2026, the Board of AB Akola Group, with its registered office at Subačiaus St. 5, Vilnius, Lithuania, company code 148030011 (the Company), approved the draft profit (loss) distribution for the Company’s 2025/2026 financial year ended 30 June 2026. The draft will be submitted for approval to the Annual General Meeting of Shareholders of the Company to be held on 28 October 2026.
The Board proposes to allocate EUR 19,825,017 for the payment of dividends, corresponding to EUR 0.12 per share of the Company before taxes (calculated excluding the Company’s own shares).
Persons who are shareholders of the Company at the end of the rights accounting date, which is 12 November 2026, will be entitled to receive dividends.
The final decision on the distribution of the Company’s profit and the payment of dividends will be made by the Annual General Meeting of Shareholders of the Company on 28 October 2026.
The Company will provide additional information on the procedure and timing for the payment of dividends once the General Meeting of Shareholders adopts a resolution to pay dividends.
Sincerely,
CEO Darius Zubas
Additional information can be provided by:
Mažvydas Šileika,
AB Akola Group Deputy CEO for Finance and Investments
Email: m.sileika@akolagroup.lt
Phone. +370 619 19 403
Hereby we announce the Annual General Meeting of Shareholders (the Meeting) of AB Akola Group, registered address Subačiaus st. 5, Vilnius, Lithuania, code 148030011, (the Company) is convened.
The date, time, and venue of the Meeting – 28 October 2026 at 10.00 a.m., Radisson Collection Astorija Hotel, Conference Hall OPERA (Didžioji St. 35/2, Vilnius, Lithuania).
The accounting day of the Meeting is 21 October 2026. Only the persons who are the shareholders of the Company at the end of the Accounting day of the Meeting shall have the right to attend and vote at the Meeting.
The Rights Accounting Day is 12 November 2026. Only the persons who are the shareholders of the Company at the end of the Rights Accounting day shall have proprietary rights.
On the day the Meeting is convened the total number of the Company’s shares is 167,170,481, and the number of shares granting voting rights is 165,208,474. The own shares in the amount of 1,962,007 acquired by the Company do not grant voting rights. The ISIN code of the Company’s shares is LT0000128092.
Agenda of the Meeting:
- Recall of the Supervisory Board and Election of a New Supervisory Board.
- Election of Audit Committee Members for a New Term and Approval of the Audit Committee Regulations.
- Presentation of the Company’s Audit Committee Activity Report, the Independent Auditor’s Report and the Independent Practitioners’ Limited Assurance Report on AB Akola Group Consolidated Sustainability Report.
- Approval of the Consolidated Annual Management Report for the 2025–2026 Financial Year Ended 30 June 2026 and the Remuneration Report, as Part of the Consolidated Annual Management Report of the Company.
- Approval of the Annual Consolidated and the Company’s Set of Financial Statements for the 2025–2026 financial year ended 30 June 2026.
- Approval of the Distribution of the Company’s Profit/Loss.
- Approval of a new wording of the Rules for Granting Shares of the Company.
The initiator of the convening of the Meeting is the Board of the Company.
The Meeting is convened by the decision of the Board of the Company, adopted on 7 October 2026.
Registration of the Shareholders of the Company starts on 28 October 2026 at 9:15 a.m.
Registration of the Shareholders of the Company ends 28 October 2026 at 9:55 a.m.
The Company does not provide a possibility to attend and vote at the Meeting through electronic means of communication.
Persons who at the end of the Accounting day of the Meeting will be shareholders of the Company, or their authorized persons, or persons with whom an agreement on the disposal of the voting right has been concluded, will have the right to personally participate and vote at the meeting.
A person attending the Meeting must submit a person’s identification document. A person who is not a shareholder must additionally produce a document confirming his/her right to vote at the Meeting.
Each shareholder shall have a right in the manner established by the Laws to authorize a natural or legal person on his/her behalf to attend and vote at the Meeting. At the Meeting, an authorized person shall have the same rights as the shareholder represented by him/her, unless otherwise specified in the issued power of attorney. A power of attorney issued abroad must be translated into Lithuanian and legalized in the manner established by the Laws. The Company does not require a special form of power of attorney.
The agenda of the Meeting may be supplemented by an initiative of the shareholders holding shares carrying at least 1/20 of all the votes. The drafts of proposed decisions on proposed issues or, if the decision shall not be adopted, an explanation on each proposed issue of the agenda of the Meeting shall be presented alongside with the proposal to supplement the agenda of the Meeting. The proposal to supplement the agenda shall be submitted in writing by sending it by registered mail to AB Akola Group at the address Subačiaus St. 5, Vilnius, Lithuania, or by e-mail info@akolagroup.lt. The agenda of the Meeting shall be supplemented if the proposal is received no later than 14 days before the Meeting (i.e. 14 October 2026).
The Supervisory Board, Board, shareholders of the Company who own shares carrying at least 1/20 of all the votes shall have the right at any time before the Meeting or during the Meeting to propose new draft decisions on the issue already included or to be included in the agenda of the Meeting. The proposed draft decisions, additional candidates for members of the Company’s bodies, auditor or audit firm, independent assurance service provider must be presented in writing by sending it by registered mail to AB Akola Group at the address Subačiaus St. 5, Vilnius, Lithuania, or by e-mail at info@akolagroup.lt, if the security of the transmitted information is ensured and the identity of individuals can be determined. The shareholders shall also be entitled to propose draft decisions on the agenda issues of the Meeting in writing during the Meeting.
The shareholders shall have the right to present questions related to the agenda issues of the Meeting to the Company. The questions in writing can be presented not later than 3 working days before the Meeting, by providing the shareholder’s personal identification number and consent to process personal data by registered mail to AB Akola Group at the address Subačiaus St. 5, Vilnius, Lithuania. Responses of a general character shall be posted on the Company’s website www.akolagroup.lt. The Company will not respond to the shareholder personally if the respective information is posted on the Company’s website.
A shareholder or a person authorized by him/her shall have the right to vote in writing in advance by filling in the General Voting Ballot. Upon a written request of the shareholder holding the voting right, the Company shall send the General Voting Ballot by registered mail not later than 10 days before the Meeting. The General Voting Ballot also will be published on the Company’s website www.akolagroup.lt. The filled-in General Voting Ballot must be signed by the shareholder or by the person authorized by him/her. If the person who is authorized by the shareholder is voting, the document confirming the right to vote must be attached to the filled-in General Voting Ballot. The document confirming the voting right must be in Lithuanian or translated into Lithuanian by an authorized translator, and his/her signature must be confirmed by notary public. The filled-in General Voting Ballot and the document confirming the voting right must be submitted to the Company in written form not later than the last working day before the Meeting, by sending it by registered mail to AB Akola Group at the address Subačiaus St. 5, Vilnius, Lithuania or personally to the Company; documents signed with a qualified electronic signature can be sent by e-mail at info@akolagroup.lt.
The shareholders can familiarize themselves with the documents, related to the agenda of the Meeting, draft decisions on each issue of the agenda, documents to be submitted to the Meeting, and other information regarding the execution of the shareholder’s rights, on the website of the Company www.akolagroup.lt, also on arrival at Subačiaus St. 5, Vilnius, Lithuania during business days at the time agreed in advance by phone number +370 663 83888 only.
Sincerely,
CEO Darius Zubas
Additional information can be provided by:
Mažvydas Šileika,
AB Akola Group Deputy CEO for Finance and Investments
Email: m.sileika@akolagroup.lt
Phone. +370 619 19 403
Attachments
- 1_Akola Group_AGM Draft Resolutions
- 2_Bendrasis_balsavimo_biuletenis_General_Voting_Ballot
- 5_Akola Group_Audito komiteto nuostatai_Audit Committee Regulations_projektas-draft
- 3_Kandidatai_Stebėtojų taryba_Candidates_Supervisory Board
- 6_Akciju suteikimo taisykles-Rules for Granting Shares_projektas-draft
- 4_Kandidatai_Audito komitetas_Candidates_Audit Committee
Hereby we announce the Annual General Meeting of Shareholders (the Meeting) of AB Akola Group, registered address Subačiaus st. 5, Vilnius, Lithuania, code 148030011, (the Company) is convened.
The date, time, and venue of the Meeting – 28 October 2026 at 10.00 a.m., Radisson Collection Astorija Hotel, Conference Hall OPERA (Didžioji St. 35/2, Vilnius, Lithuania).
The accounting day of the Meeting is 21 October 2026. Only the persons who are the shareholders of the Company at the end of the Accounting day of the Meeting shall have the right to attend and vote at the Meeting.
The Rights Accounting Day is 12 November 2026. Only the persons who are the shareholders of the Company at the end of the Rights Accounting day shall have proprietary rights.
On the day the Meeting is convened the total number of the Company’s shares is 167,170,481, and the number of shares granting voting rights is 165,208,474. The own shares in the amount of 1,962,007 acquired by the Company do not grant voting rights. The ISIN code of the Company’s shares is LT0000128092.
Agenda of the Meeting:
- Recall of the Supervisory Board and Election of a New Supervisory Board.
- Election of Audit Committee Members for a New Term and Approval of the Audit Committee Regulations.
- Presentation of the Company’s Audit Committee Activity Report, the Independent Auditor’s Report and the Independent Practitioners’ Limited Assurance Report on AB Akola Group Consolidated Sustainability Report.
- Approval of the Consolidated Annual Management Report for the 2025–2026 Financial Year Ended 30 June 2026 and the Remuneration Report, as Part of the Consolidated Annual Management Report of the Company.
- Approval of the Annual Consolidated and the Company’s Set of Financial Statements for the 2025–2026 financial year ended 30 June 2026.
- Approval of the Distribution of the Company’s Profit/Loss.
- Approval of a new wording of the Rules for Granting Shares of the Company.
The initiator of the convening of the Meeting is the Board of the Company.
The Meeting is convened by the decision of the Board of the Company, adopted on 7 October 2026.
Registration of the Shareholders of the Company starts on 28 October 2026 at 9:15 a.m.
Registration of the Shareholders of the Company ends 28 October 2026 at 9:55 a.m.
The Company does not provide a possibility to attend and vote at the Meeting through electronic means of communication.
Persons who at the end of the Accounting day of the Meeting will be shareholders of the Company, or their authorized persons, or persons with whom an agreement on the disposal of the voting right has been concluded, will have the right to personally participate and vote at the meeting.
A person attending the Meeting must submit a person’s identification document. A person who is not a shareholder must additionally produce a document confirming his/her right to vote at the Meeting.
Each shareholder shall have a right in the manner established by the Laws to authorize a natural or legal person on his/her behalf to attend and vote at the Meeting. At the Meeting, an authorized person shall have the same rights as the shareholder represented by him/her, unless otherwise specified in the issued power of attorney. A power of attorney issued abroad must be translated into Lithuanian and legalized in the manner established by the Laws. The Company does not require a special form of power of attorney.
The agenda of the Meeting may be supplemented by an initiative of the shareholders holding shares carrying at least 1/20 of all the votes. The drafts of proposed decisions on proposed issues or, if the decision shall not be adopted, an explanation on each proposed issue of the agenda of the Meeting shall be presented alongside with the proposal to supplement the agenda of the Meeting. The proposal to supplement the agenda shall be submitted in writing by sending it by registered mail to AB Akola Group at the address Subačiaus St. 5, Vilnius, Lithuania, or by e-mail info@akolagroup.lt. The agenda of the Meeting shall be supplemented if the proposal is received no later than 14 days before the Meeting (i.e. 14 October 2026).
The Supervisory Board, Board, shareholders of the Company who own shares carrying at least 1/20 of all the votes shall have the right at any time before the Meeting or during the Meeting to propose new draft decisions on the issue already included or to be included in the agenda of the Meeting. The proposed draft decisions, additional candidates for members of the Company’s bodies, auditor or audit firm, independent assurance service provider must be presented in writing by sending it by registered mail to AB Akola Group at the address Subačiaus St. 5, Vilnius, Lithuania, or by e-mail at info@akolagroup.lt, if the security of the transmitted information is ensured and the identity of individuals can be determined. The shareholders shall also be entitled to propose draft decisions on the agenda issues of the Meeting in writing during the Meeting.
The shareholders shall have the right to present questions related to the agenda issues of the Meeting to the Company. The questions in writing can be presented not later than 3 working days before the Meeting, by providing the shareholder’s personal identification number and consent to process personal data by registered mail to AB Akola Group at the address Subačiaus St. 5, Vilnius, Lithuania. Responses of a general character shall be posted on the Company’s website www.akolagroup.lt. The Company will not respond to the shareholder personally if the respective information is posted on the Company’s website.
A shareholder or a person authorized by him/her shall have the right to vote in writing in advance by filling in the General Voting Ballot. Upon a written request of the shareholder holding the voting right, the Company shall send the General Voting Ballot by registered mail not later than 10 days before the Meeting. The General Voting Ballot also will be published on the Company’s website www.akolagroup.lt. The filled-in General Voting Ballot must be signed by the shareholder or by the person authorized by him/her. If the person who is authorized by the shareholder is voting, the document confirming the right to vote must be attached to the filled-in General Voting Ballot. The document confirming the voting right must be in Lithuanian or translated into Lithuanian by an authorized translator, and his/her signature must be confirmed by notary public. The filled-in General Voting Ballot and the document confirming the voting right must be submitted to the Company in written form not later than the last working day before the Meeting, by sending it by registered mail to AB Akola Group at the address Subačiaus St. 5, Vilnius, Lithuania or personally to the Company; documents signed with a qualified electronic signature can be sent by e-mail at info@akolagroup.lt.
The shareholders can familiarize themselves with the documents, related to the agenda of the Meeting, draft decisions on each issue of the agenda, documents to be submitted to the Meeting, and other information regarding the execution of the shareholder’s rights, on the website of the Company www.akolagroup.lt, also on arrival at Subačiaus St. 5, Vilnius, Lithuania during business days at the time agreed in advance by phone number +370 663 83888 only.
Sincerely,
CEO Darius Zubas
Additional information can be provided by:
Mažvydas Šileika,
AB Akola Group Deputy CEO for Finance and Investments
Email: m.sileika@akolagroup.lt
Phone. +370 619 19 403
Attachments
- 1_Akola Group_AGM Draft Resolutions
- 2_Bendrasis_balsavimo_biuletenis_General_Voting_Ballot
- 5_Akola Group_Audito komiteto nuostatai_Audit Committee Regulations_projektas-draft
- 3_Kandidatai_Stebėtojų taryba_Candidates_Supervisory Board
- 6_Akciju suteikimo taisykles-Rules for Granting Shares_projektas-draft
- 4_Kandidatai_Audito komitetas_Candidates_Audit Committee
Inside Information
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the 2026 full-year financial outlook has been upgraded reflecting a strong growth momentum in tablet sales across regions.
- Revenue is now expected to grow by 16-17% in local currencies (previously 14-16% growth) based on growth in all sales regions and product lines with tablets as the key growth driver.
- The EBIT margin is now expected at around 27% (previously 26%), mainly reflecting operating leverage from the higher revenue outlook.
ALK will release its Q3 2026 report on 17 November 2026.
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
This announcement contains inside information. This is information that ALK-Abelló A/S is obliged to make public pursuant to the EU Market Abuse Regulation.
About ALK
ALK is a global specialty pharmaceutical company focused on allergy. ALK’s activities cover the entire value chain of developing, sourcing, producing, and marketing a diversified portfolio of products for diagnosing and treating respiratory allergies and severe allergic reactions (anaphylaxis) in both children and adults. Headquartered in Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen (Nasdaq: ALK B). Visit us at www.alk.net.
Attachment
Inside Information
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the 2026 full-year financial outlook has been upgraded reflecting a strong growth momentum in tablet sales across regions.
- Revenue is now expected to grow by 16-17% in local currencies (previously 14-16% growth) based on growth in all sales regions and product lines with tablets as the key growth driver.
- The EBIT margin is now expected at around 27% (previously 26%), mainly reflecting operating leverage from the higher revenue outlook.
ALK will release its Q3 2026 report on 17 November 2026.
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
This announcement contains inside information. This is information that ALK-Abelló A/S is obliged to make public pursuant to the EU Market Abuse Regulation.
About ALK
ALK is a global specialty pharmaceutical company focused on allergy. ALK’s activities cover the entire value chain of developing, sourcing, producing, and marketing a diversified portfolio of products for diagnosing and treating respiratory allergies and severe allergic reactions (anaphylaxis) in both children and adults. Headquartered in Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen (Nasdaq: ALK B). Visit us at www.alk.net.
Attachment
REGULATED INFORMATION
Courbevoie, France – October 07, 2026
Information on number of shares and voting rights as provided
by article 223-16 of the general regulations of the
French financial markets authority AMF
Issuer: Bureau Veritas
| Date | Number of shares (1) | Number of voting rights |
| 30/09/2026 | 453,899,720 | Theoretical number of voting rights: 579,456,124 Number of exercisable voting rights: 569,351,911 |
(1) including the new shares issued in Euroclear as a result of the exercise of stock options since January 1, 2026, if any.
| Bureau Veritas | Head Office | Tel: + 33 (0)1 55 24 70 00 |
| Société Anonyme | Tour Alto | Fax: + 33 (0)1 55 24 70 01 |
| (Limited liability corporation) | 4, Place des Saisons | www.bureauveritas.com |
| Share capital of EUR 54,464,582.40 | 92400 Courbevoie | |
| RCS Nanterre 775 690 621 | France |
Attachment
